[Clinical features of enterohemorrhagic E. coli gastrointestinal infection].
Igarashi
Takashi
T
Department of Pediatric Science, Division of Reproductive, Developmental and Aging Science, Graduate School of Medicine, The University of Tokyo.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003956:Dialysis; D004573:Electrolytes / Q000008:administration & dosage; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy; D019453:Escherichia coli O157 / Q000378:metabolism / Q000472:pathogenicity; D005440:Fluid Therapy; D005578:Fosfomycin / Q000627:therapeutic use; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D011379:Prognosis; D022603:Shiga Toxins / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D004573:Electrolytes; D022603:Shiga Toxins; D005578:Fosfomycin